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Abstract: It has been 35 years since Professor Thoenes and his colleagues discovered chromophobe renal
cell carcinoma (RCC). Since then, our knowledge about this tumour entity has changed and novel tumour
entities have been discovered. The aim of this review is to discuss recent molecular findings and open
questions in diagnosing chromophobe-like/oncocytic neoplasms. The broader differential diagnosis of
chromophobe-like and oncocytoma-like neoplasms includes SDH-deficient renal cell carcinoma, fumarate
hydratase (FH) deficient RCC, epitheloid angiomyolipoma (’oncocytoma like’), MiT family translocation
RCC and the emerging entity of eosinophilic solid and cystic renal cell carcinoma. After separation of
these tumours from chromophobe RCC, it becomes evident that chromophobe RCC are low malignant
tumours with a 5-6% risk of metastasis. Recent next generation sequencing (NGS) and DNA methylation
profiling studies have confirmed Thoenes’ theory of a distal tubule derived origin of chromophobe RCC
and renal oncocytomas. Comprehensive genomic analyses of chromophobe RCC have demonstrated a low
somatic mutation rate and identified TP53 and PTEN as the most frequently mutated genes, whereas
’unclassified’ RCC with oncocytic or chromophobe-like features can show somatic inactivating mutations
of TSC2 or activating mutations of MTOR as the primary molecular alterations. For the future, it would
be desirable to create a category of ’oncocytic/chromophobe RCC, NOS’ with the potential of further
molecular studies for identification of TSC1/2 mutations in these rare tumours.
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Summary
It has been 35 years since Professor Thoenes and his
colleagues discovered chromophobe renal cell carcinoma
(RCC). Since then, our knowledge about this tumour entity
has changed and novel tumour entities have been
discovered. The aim of this review is to discuss recent
molecular findings and open questions in diagnosing
chromophobe-like/oncocytic neoplasms. The broader dif-
ferential diagnosis of chromophobe-like and oncocytoma-
like neoplasms includes SDH-deficient renal cell carci-
noma, fumarate hydratase (FH) deficient RCC, epitheloid
angiomyolipoma (‘oncocytoma like’), MiT family trans-
location RCC and the emerging entity of eosinophilic solid
and cystic renal cell carcinoma. After separation of these
tumours from chromophobe RCC, it becomes evident that
chromophobe RCC are low malignant tumours with a
5–6% risk of metastasis. Recent next generation
sequencing (NGS) and DNA methylation profiling studies
have confirmed Thoenes’ theory of a distal tubule derived
origin of chromophobe RCC and renal oncocytomas.
Comprehensive genomic analyses of chromophobe RCC
have demonstrated a low somatic mutation rate and
identified TP53 and PTEN as the most frequently mutated
genes, whereas ‘unclassified’ RCC with oncocytic or
chromophobe-like features can show somatic inactivating
mutations of TSC2 or activating mutations of MTOR as the
primary molecular alterations. For the future, it would be
desirable to create a category of ‘oncocytic/chromophobe
RCC, NOS’ with the potential of further molecular studies
for identification of TSC1/2 mutations in these rare
tumours.
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RECOGNITION OF CHROMOPHOBE RENAL
CELL CARCINOMA
In the 1975 United States Armed Forces Institute of Pathology
(AFIP) Atlas of Tumour Pathology1 and the 1981 World
Health Organization (WHO) classification,2 renal cell carci-
noma (RCC) was mainly diagnosed as ‘renal
adenocarcinoma’, but it was evident that histological
subtyping was of prognostic significance.3 Classification at-
tempts before 1950 included subtypes according to the pre-
dominant cytoplasmic or architectural features with clear cell
carcinomas, papillary carcinomas and granular cell carci-
nomas.4 Renal tumours that were composed of ‘oncocytes’
had been already described in 1942. This name came from the
dominant cell type of large, eosinophilic cells with granular
cytoplasm. Later, oncocytoma was accepted as a benign renal
tumour entity, but there were already descriptions of malig-
nant forms of oncocytomas, which were probably chromo-
phobe RCC.3,5 In 1985 and 1988, Thoenes et al. reported on
RCCs composed of ‘chromophobe’ cells.6,7 This designation
resulted from an observation of Bannasch et al. in 1974 in
nitrosomorpholine-induced renal neoplasia in rats.8 These
tumours in rats showed a peculiar histomorphology; by light
microscopy, ‘chromophobe’ cells had a slightly opaque finely
reticular cytoplasm when stained with haematoxylin and
eosin. In the 1980s, classification proposals for human RCC
used characteristic cellular features for their entities. With the
recognition of a ‘chromophobe’ RCC subtype, Thoenes et al.
proposed in 1986 theMainz classification system (Fig. 1) with
tumour subtypes classified consequently on the basis of pre-
dominant cytoplasmic staining characteristics.9 They sepa-
rated clear cell carcinoma from chromophilic carcinoma and
chromophobe RCCs, and added Bellini duct carcinoma on the
basis of the ‘cell of origin’ concept. Cells of chromophobe
RCC were distinguished from the clear cells of clear cell
carcinoma and eosinophilic cells of ‘chromophilic’ papillary
carcinoma. In contrast to oncocytoma, chromophobe RCC
showed a strong positive reaction of their cytoplasm with
Hale’s colloidal iron method. In the following years, the
Mainz classification was validated by cytogenetic studies,
mainly performed by Kovacs.10–12 Most importantly, chro-
mophobe RCC was characterised by a unique genetic back-
ground with loss of heterozygosity 1, 2, 6, 10, 13, 17, 21 and
hypodiploidy on flow cytometry studies in addition to its
typical histological appearance.13 At the 1997 Heidelberg
conference, the molecular background of different renal
cancer subtypes was introduced into a classification system.14
As a result of the Heidelberg/Rochester consensus confer-
ences, the 1998 WHO classification gave chromophobe RCC
its own entity, 12 years after the Mainz classification.15 The
2004 and 2016 WHO classifications define chromophobe
RCC as the third most common subtype of RCC.16,17
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Fig. 1 Mainz Classification with a scheme of the various nephron/collecting duct segments and their different phenotypical relation to the classified epithelial renal cell
tumours.3
Fig. 2 Morphological heterogeneity of chromophobe renal cell carcinoma (RCC). (A) Chromophobe RCC consisting of both cell types, eosinophilic and pale cells.
(B–E) Intratumoural heterogeneity of CK7 staining in chromophobe RCC. (B) Tumour area almost purely composed of eosinophilic cells. Note perinuclear halos. (C)
Tumour area with CK7 positivity in single cells, similar to oncocytomas. Note bi-nucleated tumour cells. (D) Tumour area with groups of CK7-positive cells, typical for
chromophobe RCC. (E) Tumour area with diffuse and strong CK7 staining. (F) Chromophobe RCC with sarcomatoid differentiation.
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Since the first description by Thoenes et al., epidemiology
and pathological features of chromophobe RCC have been
extensively studied.18–23 Chromophobe RCC accounts for
approximately 5–7% of RCC. Most tumours are sporadic.
Birt–Hogg–Dubé (BHD) syndrome, an autosomal dominant
disorder associated with mutation in the Folliculin gene,24
and Cowden syndrome with germline mutations in PTEN
are associated with a higher incidence of chromophobe-like
or oncocytoma-like neoplasms.
Chromophobe RCC are characteristically well circum-
scribed but not encapsulated. Whereas most oncocytoma have
a brown or mahagony colour, the cut surface of classic
chromophobe RCC is grey or light tan. Histologically, they
grow predominantly in solid sheets, separated by vascular
septs (Fig. 2A,B). Some tumours show variable nested,
trabecular, alveolar, microcystic or even papillary patterns.25
A small percentage exhibits sarcomatoid growth26 (Fig. 2F).
Classic tumours show predominance of pale cells with clear
cytoplasm. The cytoplasm is translucent and finely reticulated,
sometimes microvesiculated. Some larger cells with more
voluminous clear to foamy (‘hydropic’) cytoplasm are often
present among pale cells. Another cell type is characterised by
densely eosinophilic or granular cytoplasm (Fig. 2B). Pale and
eosinophilic cell types can be mixed (Fig. 2A). Hyper-
chromatic nuclei with irregular, wrinkled outlines (‘raisinoid’)
are most characteristic. Another characteristic feature is
presence of perinuclear cytoplasmic clarity (so called peri-
nuclear halos). Binucleated cells are present in virtually all
cases. Cell membranes usually appear prominent (‘plant cell-
like’), an important criterion compared to oncocytoma.
Hyperchromatic bizarre nuclear atypia similar to those in renal
oncocytoma can be common. The prevalence of sarcomatoid
differentiation ranges from 1.8% to 8.8%.27,28 Mitotic activity
is very uncommon in chromophobe RCC. Since the first
description of chromophobe RCC, the differential diagnosis
between renal oncocytoma and chromophobe RCC remains
difficult in some cases. A recent survey among urological
pathologists regarding oncocytic tumours showed that most
pathologists used immunohistochemistry for this separation.29
More than one mitotic figure was regarded as incompatible
with oncocytoma diagnosis by many uropathologists. Minor
areas with nuclear wrinkling, focal perinuclear clearing, and




For many years, electron microscopy was used to diagnose
oncocytomas and chromophobe RCC. Thoenes et al. reported
on vesicular structures possibly derived from the endo-
plasmic reticulum or from mitochondria chromophobe RCC
and oncocytomas.7,9 Several ultrastructural studies have
shown that the typical cells of chromophobe RCC (‘pale
cells’) are characterised by numerous cytoplasmic micro-
vesicles, a feature probably related to defective mitochondrial
development. In more eosinophilic cells of chromophobe
RCC, mitochondria are very abundant.2,6–30 Thoenes et al.
also used colloidal (Hale’s) iron staining, demonstrating a
variable granular or reticular and diffuse cytoplasmic staining
in most chromophobe RCC in contrast to oncocytomas.7
However, colloidal (Hale’s) iron staining is nowadays less
popular, because some chromophobe RCC show only focal
or weak or even luminal-type staining.29 Immunohis-
tochemically, CK7 is a very important marker, showing
diffuse expression in more than 75% of chromophobe RCC31
(Fig. 2C–E). Occasionally, there are only a few clusters of
weak cells with membranous accentuation. Such CK7-
positive cell clusters should not be present in oncocytomas,
but CK7-positive cells can be present around the central scar
of an oncocytoma. CD117 and Ksp-Cadherin are diffusely
positive in the overwhelming majority of chromophobe
RCCs. Most cases also show positivity with MOP-31,
Claudin-7 and EpCAM (BerEP4).32 CA9 is negative and
also CD10 is usually negative but may show focal positiv-
ity.33 Rare CK7-positive cells (5% as single cells, not
clusters) are regarded as most supportive of oncocytoma.29
MOLECULAR STUDIES AND THE ‘CELL OF
ORIGIN’ THEORY
Thoenes assumed that chromophobe RCC had a different
histogenetic derivation than clear cell and other RCCs.34–36
On the basis of a different histology and immunoprofile, he
argued that chromophobe renal cancer and oncocytoma were
derived from the intercalated cells of the distal tubules in the
renal cortex (Fig. 1). This concept is still controversial,
because the cancer stem cell theory with tumourigenic stem
cells rather than terminally differentiated tubular cells is also
relevant for many RCC subtypes.37,38 Interestingly, a recent
next generation sequencing (NGS) analysis identified FOXI1,
RHCG, and LINC01187 in classic and eosinophilic chromo-
phobe RCCs, as well as metastatic chromophobe RCC.39
These biomarkers are also expressed in other oncocytic renal
neoplasms, including unclassified RCC with oncocytic fea-
tures, hybrid oncocytic and chromophobe tumours, and
oncocytomas, but not in other renal tumour subtypes. FOXI1
is an essential transcription factor for differentiation of distal
tubule intercalated cells. This finding is somehow in line with
Thoenes’ ‘cell of origin’ theory for oncocytic renal tumours.
Recent DNA methylation profiling and single cell sequencing
studies have identified chromophobe RCC specific methyl-
ation with similarities to distal tubule methylation patterns.40,41
Various cytogenetic, comparative genomic hybridisation
and recent molecular and proteome studies have confirmed
the very unique and characteristic genotype, with multiple
chromosomal losses of chromosomes 1, 2, 6, 10, 13, 17, 21
and sex chromosome in the majority of chromophobe
RCCs.13,42,43 Genomic instability, including whole chromo-
some aneuploidy, is a hallmark of human cancer. Given the
level of chromosomal losses in chromophobe RCC, tumour
growth must be the consequence of a special molecular
pathway. The phenomenon of tumour cell growth in spite of
multiple chromosomal losses can be potentially explained by
involvement of CYCLOPS (Copy number alterations
Yielding Cancer Liabilities Owing to Partial losS) genes.
CYCLOPS genes receive little feedback regulation in their
expression when altered by somatic copy number alterations.
Splicing factor 3B subunit 1 (SF3B1) belongs to this group of
CYCLOPS genes and has been recently identified as a po-
tential novel, non-driver cancer gene in chromophobe RCC.44
Given an accumulation of mitochondria in chromophobe
RCC and oncocytoma, it is tempting to search for alterations
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in mtDNA. Indeed, some studies have disclosed frequent
somatic mtDNA mutations in oncocytoma and chromophobe
RCC,45–47 but mtDNA mutations are not specific for chro-
mophobe RCC.48
Comprehensive genomic analyses of chromophobe RCC
cohorts demonstrated a low somatic mutation rate in chro-
mophobe RCC and identified TP53 and PTEN as the most
frequently mutated genes.48–51 Mutation rates of TP53 and
PTEN were higher in chromophobe RCC patients with met-
astatic disease52 and with sarcomatoid features.
CDKN1A, which resides in 6p21.2, is affected by frequent
loss of one chromosome 6 allele in chromophobe RCC.53
Analysis of TCGA data of chromophobe RCC demon-
strated that loss of one CDKN1A allele was closely linked to
lower CDKN1A mRNA expression levels. It has been
recently shown that decreased CDKN1A expression at
mRNA and protein levels were associated with short overall
survival and were independent predictors of prognosis in
chromophobe RCC.
Other NGS analyses as well as the combination of gene
expression and proteome profiles, high throughput SNP
genotyping, and pathway analysis have been used to distin-
guish chromophobe RCC from oncocytoma and confirm
dysregulated pathways of c-erbB2 and mammalian target of
rapamycin (mTOR) signalling in chromophobe
RCC.39,50,54–57
ARE THERE SUBTYPES OF CHROMOPHOBE
RCC?
Eosinophilic subtype
Thoenes et al. used the term ‘chromophobe cell’ for larger
cells with reticular, but not clear cytoplasm and prominent
cell membranes (‘plant cell-like’).7 Three years later, these
authors described eosinophilic cells with smaller size and
with fine oxyphilic granularity as a second cell component of
chromophobe RCC.6 Crotty et al. used the term ‘pale cell’
instead of the formerly used term ‘chromophobe cell’, and
considered ‘pale cell’ and ‘eosinophilic cell’ as two main cell
types in chromophobe RCC.18 Most chromophobe RCCs
consist of both cell types, which are typically mixed, with
eosinophilic cells usually arranged at the centre and pale cells
usually arranged at the periphery of the sheets or nests. The
current 2016 WHO classification states that eosinophilic
chromophobe RCC ‘is almost purely composed of eosino-
philic cells’ and that ‘the majority of cells should be eosin-
ophilic cells’,17 but there is currently a lack of exact criteria to
clearly define the eosinophilic subtype of chromophobe
RCC. As a consequence of this lack of stringent criteria for
subtyping chromophobe RCC, distribution of chromophobe
RCC variants varies extremely between different studies and
it is difficult to demonstrate molecular differences between
both groups.58,59 Ohashi et al. have recently shown that there
is no difference in the prognosis of ‘classic’ and ‘eosino-
philic’ chromophobe RCC.58 Therefore, the value of report-
ing the eosinophilic variant of chromophobe RCC is to
remind people that they can be mistaken for oncocytomas.
Hybrid oncocytic and chromophobe tumours
Some chromophobe tumours demonstrating nuclear pleo-
morphism and mitotic index beyond that acceptable for
oncocytoma were initially described in patients with BHD
syndrome. By conventional pathological examination, hybrid
oncocytic and chromophobe tumours harbour a mixture of
cells with morphological and immunophenotypical features
that overlap with those of renal oncocytoma and chromo-
phobe RCC. Therefore, the term ‘hybrid oncocytic and
chromophobe tumour’ was proposed20 and is now variably
used in several scenarios, including tumours in BHD syn-
drome, oncocytomatosis and for sporadic cases.60–62 Un-
fortunately, the morphological criteria are not exactly
defined. Some hybrid oncocytic and chromophobe tumours
show a mosaic pattern with defined renal oncocytoma-like
zones with solid nests/alveoli in close contact to chromo-
phobe RCC-like zones (Fig. 2), whereas others show an
ambiguous morphology with oncocytoma-like architecture,
but absence of nuclear wrinkling and perinuclear halos as
seen in the extent of chromophobe RCC.
The 2016 WHO classification includes a statement that a
small subset of tumours have overlapping histology between
oncocytoma and chromophobe RCC and recommends that
such tumours should be designated as hybrid oncocytic and
chromophobe tumour. There is evidence that the metastatic
rate of hybrid oncocytic and chromophobe tumours ranges
between 2% in a sporadic setting20,60,63–67 and 5% in a BHD
syndrome setting.68,69 This is comparable to chromophobe
RCC with a low metastatic rate of <10%. The designation of
hybrid oncocytic and chromophobe tumour as its own tumour
category is controversial, with authors suggesting that hybrid
oncocytic and chromophobe tumours represent a variant of
classic renal oncocytoma and others as variant of the eosin-
ophilic variant of chromophobe RCC.60,61 A very recent and
comprehensive study by Ruiz-Cordero et al. studied hybrid
oncocytic and chromophobe tumour by gene expression
profiling and targeted NGS and compared the results with
chromophobe RCC and renal oncocytoma.62 Hybrid onco-
cytic and chromophobe tumours were more frequently
multifocal and did not exhibit mutations in genes that are
recurrently mutated in renal oncocytoma or chromophobe
RCC, but they showed copy number alterations primarily
involving losses in chromosomes 1 and X/Y. mRNA tran-
script data separated hybrid oncocytic and chromophobe
tumour from renal oncocytoma and chromophobe RCC.
Based on these results, the authors concluded that hybrid
oncocytic and chromophobe tumour represents a renal
tumour variant that is intermediate between renal oncocyto-
ma and chromophobe RCC.
A recent survey among uropathologists revealed that for
tumours with mixed or inconclusive features, many partici-
pants use an intermediate diagnostic category that does not
label the tumour as unequivocally benign or malignant,
typically ‘oncocytic neoplasm’ or ‘tumour’ with comment.29
Therefore, most participants at the International Society of
Urological Pathology (ISUP) conference indicated that they
view hybrid oncocytic and chromophobe tumour as a subset
of chromophobe RCC.70 Overlapping histology between
oncocytoma and chromophobe RCC reflects intratumoural
heterogeneity of chromophobe RCC rather than its own
subtype.
Is oncocytoma a precursor lesion of chromophobe
RCC?
Thoenes et al. argued that there are no precursor lesions of
chromophobe RCC. Given the similarity of the eosinophilic
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variant of chromophobe RCC and oncocytoma, one might
hypothesise that oncocytoma represents the benign counter-
part of chromophobe RCC. In a recent study, almost all
eosinophilic and all classic chromophobe RCC revealed
chromosome 1 loss, suggesting that this may be an early
event in chromophobe RCC tumourigenesis. The only mo-
lecular alteration shared by chromophobe RCC and renal
oncocytoma is loss of chromosome 1,58,71–73 consistent with
a speculation by Tan et al. that this may represent an early
event in neoplastic transformation of a common progenitor
cell in both chromophobe RCC and renal oncocytoma.54 In
oncocytomas, chromosome 1 loss may precede other mo-
lecular events leading to malignancy in lesions that progress
to chromophobe RCC. This situation is comparable to chro-
mosome 3p loss in clear cell RCC, which is thought to be an





During the last decade, unequivocal recognition of chromo-
phobe RCC with a typical histology and immunophenotype
has allowed the separation of other renal tumour entities with
oncocytoma/chromophobe-like histomorphology. The most
important differential diagnosis is SDH-deficient RCC,74,75 a
tumour entity very similar to chromophobe RCC. It is
important to recognise these tumours because they represent a
hereditary tumour entity. The broader differential diagnosis
of chromophobe-like and oncocytoma-like neoplasms may
now include tumours occurring in patients with BHD syn-
drome, fumarate hydratase (FH)-deficient RCC, epitheloid
angiomyolipoma (‘oncocytoma-like’), MiT family (TFE3 or
TFEB) translocation RCC and the emerging entity of eosin-
ophilic solid and cystic (ESC) RCC with a characteristic
CK20 expression.
Tumours with TSC alterations
Most importantly, recent studies have identified many tu-
mours with eosinophilic cytoplasm and oncocytic or
chromophobe-like features in the group of ‘unclassified’
RCC. Li et al. reviewed 33 unclassified RCCs with pre-
dominantly eosinophilic cytoplasm in patients aged 35 years
or younger.76 They identified SDHB-deficient, FH-deficient
and ESC cases, but 33% remained ‘unclassified’. Perrino
et al. analysed 136 unclassified RCC and assigned them to the
following morphological groups: predominantly oncocyto-
ma/chromophobe RCC-like; clear cell RCC-like; papillary
RCC-like; collecting duct-like; and pure sarcomatoid differ-
entiation.77 The majority (73%) was predominantly renal
oncocytoma-like/chromophobe RCC-like phenotype. Inter-
estingly, different groups have very recently analysed ‘un-
classified’ RCC with chromophobe-like or renal
oncocytoma-like RCC and with eosinophilic or vacuolated
cytoplasm by targeted NGS. Although the morphology of
these cases was very close to renal oncocytoma or the
eosinophilic variant of chromophobe RCC, these tumours
ended up in the ‘unclassified’ RCC category because of an
unusual histology or immunophenotype with a dense and
more abundant eosinophilic cytoplasm, diffuse staining of
CK7, absent to weak staining of CK20 or positivity for
P504S.78,79 Chen et al. studied five cases and Tjota et al. 18
cases. Both groups identified somatic inactivating mutations
of TSC2 or activating mutations of MTOR as the primary
molecular alterations, consistent with hyperactive mTOR
complex 1 (mTORC1) signalling in most chromophobe-like
or renal oncocytoma-like cases.
ESC RCC with CK20 expression can also show TSC gene
mutations or biallelic losses.80 Interestingly, some ESC RCC
have solid areas with chromophobe-like appearance.81
Moreover, ESC tumours have recently been described as a
sporadic form of RCC with histological similarity to a subset
of renal tumours encountered in TSC patients. Some authors
argue that somatic mutations of TSC2 orMTOR characterise a
morphologically distinct subset of sporadic RCC with
eosinophilic and vacuolated cytoplasm. However, TSC/
MTOR associated neoplasms are a morphologically and
immunohistochemically heterogeneous group. TSC/MTOR
associated neoplasms include eosinophilic renal tumours
with a chromophobe-like appearance with perinuclear halos.
Some of these tumours are diffusely positive for CK7 but
negative (or only focally positive) for CK20. Trpkov et al.
proposed the term ‘low grade oncocytic tumours’ (LOT) with
CD117 negativity and CK7 positivity as an emerging renal
tumour entity with indolent clinical behaviour,82 but further
studies are warranted to prove that LOT really represents a
distinct type of tumour. For the time being, they should be
regarded as variant of unclassified ‘chromophobe-like’ RCC.
So-called RCC ‘with prominent leiomyomatous stroma’ also
frequently harbour TSC1/TSC2, MTOR, and/or ELOC
(TCEB1) mutations, consistent with hyperactive mTOR
complex.83 These tumours can have some morphological
overlap with ccRCC and clear cell papillary RCC, supporting
the hypothesis that previously published TCEB1 (ELOC)
mutated RCCs are identical, and indistinguishable from a
subset of hereditary TSC associated RCCs, originally
described as ‘RAT-like’ or ‘TSC associated papillary type.’
In summary, it would be desirable to create a new category
of ‘oncocytic/chromophobe RCC, NOS’. The main advan-
tage for creating this category is the potential of further
molecular studies for identification of TSC1/2 mutations.
According to recently published data, such tumours have a
good prognosis, but identification of TSC mutations by NGS
could suggest a treatment by mTOR inhibitors. In contrast, a
category of TSC1/2 mutated RCC would encompass a cate-
gory of tumours with an extremely broad histological spec-
trum, which is only molecularly defined and cannot be
diagnosed by histology alone.
PROGNOSIS AND GRADING OF
CHROMOPHOBE RCC
Thoenes et al. had already argued that chromophobe RCC
may have a better prognosis than clear cell RCC, but his
series of 13 and 33 tumours were too small to prove this
hypothesis.6,7 Meanwhile several large studies have indi-
cated that prognosis of chromophobe RCC is much better
than that of clear cell RCC and papillary RCC. Most chro-
mophobe RCC have a favourable outcome and low risk of
metastasis, but there is evidence that chromophobe RCC
have a predisposition to metastasise into the liver.84 Ten year
overall survival rates of between 80 and 90% have been
reported.20,22,85,86 It is important to note that tumour specific
survival or time to tumour progression are much more
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important than overall survival measures, because death of
disease occurs only in about 5–6% of patients with chro-
mophobe RCC.26 Clinically, it would be extremely helpful
to identify this small subgroup at increased risk for
metastasis.
Numerous studies have confirmed that tumour size and the
presence of sarcomatoid morphology indicates poor prog-
nosis and increased risk of metastatic development for
chromophobe RCC.23,28,85–88 Tumour grade is also impor-
tant, but the four tiered nuclear grading system proposed by
ISUP could not be validated for chromophobe RCC, because
they have an innate constitutive atypia including prominent
nucleoli, nuclear irregularities and bi-nucleation.89 In the
past, there have been several attempts to develop a grading
system for chromophobe RCC,20–22,27,85,86,90,91 considering
the inherent geographic nuclear crowding and presence of
anaplasia. Paner et al. suggested a three tiered chromophobe
tumour grading scheme and supplemented nuclear grading
with additional variables including geographic nuclear
crowding and objective nuclear size.86 With this approach,
the majority of chromophobe RCCs are of a lower grade, but
there is inter- and intra-observer variability in the identifica-
tion of nuclear crowding and nuclear pleomorphism. Lohse
et al. applied a four tiered standardised grading for chromo-
phobe RCC and demonstrated a significant overlap in grades
3, 2 and 1 chromophobe RCC.92
Recently, a two tiered grading system (low vs high grade)
was proposed by Ohashi et al., using sarcomatoid differen-
tiation and presence of tumour necrosis as parameters.26 The
advantages of this two tiered grading system over previous
proposals of three or four tiered grading systems, are a high to
very high concordance between different pathologists, and a
high reliability in identification of patients with increased risk
of chromophobe RCC progression. Metastasis of low grade
tumours was absent in four different cohorts from Japan,
Germany, Switzerland and Italy.
TREATMENT OF METASTATIC
CHROMOPHOBE RCC
Patients with high grade tumours (sarcomatoid differentiation
and/or tumour necrosis) should have a stringent follow-up
because of their increased risk of metastasis.23 Because
metastasis of chromophobe RCC is very rare, dedicated
prospective clinical trials for metastatic chromophobe RCC
are not available and patients are treated as non-clear cell
RCC. Favourable responses to VGF-tyrosine kinase inhibitor
agent, mTOR inhibitors and immune checkpoint inhibitors
have been reported. Sarcomatoid differentiation in chromo-
phobe RCC is an indicator of limited response to systemic
therapy and poor overall survival.28 However, the immuno-
logical landscape of renal tumour with sarcomatoid areas
shows a different molecular background with frequent
expression of programed cell death ligand-1 (PD-L1) and
high levels of tumour infiltrating lymphocytes.93,94 These
determinants explain the activity of immune checkpoint in-
hibitors in RCC with sarcomatoid differentiation. This has
been confirmed by retrospective studies and subgroup ana-
lyses of large randomised phase 3 trials.
Therefore, immune checkpoint inhibitor combinations
could also be relevant in patients with metastatic chromo-
phobe RCC with sarcomatoid differentiation.95,96 Patients
with metastatic chromophobe RCC might be considered for
targeted NGS testing. If there is a molecular mutation,
appropriate molecular targeted therapy can be provided. This
is particularly critical for TSC associated ‘chromophobe-like’
RCCs as there are mTOR inhibitors currently available for
the treatment of RCCs.97 A few case reports have demon-
strated clinical benefit in using mTOR inhibitors to treat TSC
associated RCCs, including complete response in a case of
sporadic, metastatic ESC RCC.78,98 Interestingly, one of the
cases described as responding to mTOR inhibitor therapy was
originally diagnosed as chromophobe RCC. The patient was
found to have a germline TSC1 mutation without other
characteristics of a TSC tumour.99
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